Kyeong Hyeon LEE

Dr. Kyeong Hyeon LEE

Regulatory Pharmacy, Chung-Ang University, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SPSang Mi Park
Sang Mi Park
DKDa Yeon Kim
Da Yeon Kim
Kyeong Hyeon LEEKyeong Hyeon LEE
Kyeong Hyeon LEE
YSYong-Il Shin
Yong-Il Shin
SHSang-Cheol Han
Sang-Cheol Han
SKSang Mo Kwon
Sang Mo Kwon
Purpose: 5-fluorouracil (5-FU) is a first-line chemotherapeutic agent used to treat colorectal cancer (CRC). However, 5-FU induces drug resistance and activation of cancer stem cells (CSCs). In the present study, we designed a novel biocompatible nanomedicine system with high efficacy and biocompatibility by synthesizing mesoporous silica nanoparticle (MSN)-structured ZnO and gold ions. Oleuropein (OLP) is a phenolic compound derived from olive leaves that exerts anti-cancer effects. Therefore, we synthesized OLP-loaded ZnO/Au MSNs (ZnO/Au/OLP MSNs) and examined their anti-cancer effects on 5-FU-resistant CRC cells. Methods: ZnO/Au MSNs were synthesized and functionalized, and their physical and chemical compositions were characterized using UV-visible spectroscopy, dynamic light scattering, and transmission electron microscopy (TEM). Their effects were assessed in terms of cellular proliferation capacity, migration and invasion ability, colony-forming ability, spheroid-forming ability, reactive oxygen species (ROS) production, and mitochondrial membrane depolarization. Results: ZnO/Au MSNs were mostly composed of various ions containing ZnO and gold ions, had a spheroid phenotype, and exhibited no cytotoxicity. ZnO/Au/OLP MSNs reduced cell viability and CSC formation and induced apoptosis of 5-FU-resistant CRC cells via necrosis via ROS accumulation and DNA fragmentation. Conclusion: ZnO/Au/OLP MSNs exhibited anti-cancer activity by upregulating necrosis. These results revealed that ZnO/Au/OLP MSNs are a novel drug delivery system for 5-FU CRC therapy.

19 January 2024 in International Journal of Bioprinting
Verified
Journal Article
Open access
PDF file
KYKyeongWoong Yang
KyeongWoong Yang
DLDonghyun Lee
Donghyun Lee
KLKyoung Ho Lee
Kyoung Ho Lee
WJWoong Bi Jang
Woong Bi Jang
HLHye Ji Lim
Hye Ji Lim
SKSang Mo Kwon
Sang Mo Kwon
AccScience Publishing is a publishing company based in Singapore. We have in our portfolio a range of high-quality, open-access, peer-reviewed journals and books from a broad spectrum of science, technology, biomedicine, engineering, education, social sciences and many more.

21 January 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JLJae Ho Lee
Jae Ho Lee
Kyeong Hyeon LEEKyeong Hyeon LEE
Kyeong Hyeon LEE
JRJi Hyeon Ryu
Ji Hyeon Ryu
MKMin Jae Kim
Min Jae Kim
EKEunji Kim
Eunji Kim
HSHwa-Kyoung Shin
Hwa-Kyoung Shin
Stroke is globally recognized as the second leading cause of death, significantly impairing both motor and cognitive functions. Enhancing regeneration after stroke is crucial for restoring these functions and necessitates strategies to promote neuroregeneration to achieve better post-stroke outcomes. Brain-derived neurotrophic factor (BDNF) plays a key role in neuroregeneration by influencing motor ability, learning, memory, and rehabilitation after stroke. However, challenges such as the substantial protein size, short half-life of BDNF, and blood-brain barrier hinder its efficient delivery to the brain. In this study, LM22A-4, a BDNF mimetic, was utilized and delivered through a Smart Mesoporous Ball (SMB-3) system to target the ischemic injured brain and explore its potential therapeutic effects in a mouse ischemic stroke model. Treatment with LM22A-4-loaded SMB-3 (LM22A-4-SMB-3) markedly restored neurological, motor, and cognitive deficits following ischemic stroke compared to LM22A-4 alone. Additionally, administration of LM22A-4-SMB-3 reduced apoptotic cell death and glial activation, as evidenced by the TUNEL assay results, and decreased GFAP and Iba-1 expression levels. Furthermore, the phosphorylation of TrkB and Akt, but not that of Erk, was considerably increased in the LM22A-4-SMB-3-treated group. Treatment also enhanced the number of BrdU+/NeuN+ cells, with a marked reduction in post-stroke brain atrophy. These findings suggest that LM22A-4-SMB-3 can attenuate ischemic damage and recover neurological, motor, and cognitive functions by increasing p-TrkB and p-Akt levels and promoting neurogenesis. Therefore, SMB-3-mediated delivery of LM22A-4 presents a potentially applicable delivery system, and LM22A-4-SMB-3 use could be considered a novel therapeutic strategy to improve post-stroke outcomes.

15 January 2024 in International Journal of Bioprinting
Verified
Journal Article
Open access
PDF file
JCJaewoo Choi
Jaewoo Choi
JZJie Zhang
Jie Zhang
HLHye Ji Lim
Hye Ji Lim
DLDong Myoung Lee
Dong Myoung Lee
DYDeokhyeon Yoon
Deokhyeon Yoon
SKSang Mo Kwon
Sang Mo Kwon
Vascular diseases, including ischemic conditions and restenosis, pose significant challenges in clinical practice. Restenosis, the re-narrowing of blood vessels after interventions such as stent placement, remains a major concern despite advances in medical interventions. Addressing these challenges requires innovative approaches that promote vascular regeneration and prevent restenosis. By leveraging the capabilities of three-dimensional (3D) printing technology, artificial blood vessels with lumen can be precisely constructed in customizable sizes, closely mimicking the natural vascular architecture. This approach allows for the incorporation of therapeutic agents and cells to enhance the functionality of the fabricated vessels. In the present study, we investigated the fabrication and characterization of artificial blood vessels using 3D printing technology, with the focus on achieving precise control over the vessel dimensions and architecture to ensure optimal functionality. The use of 3D printing enabled the creation of patient-specific blood vessels with tailored sizes and geometries, providing a personalized solution for vascular treatment. Furthermore, we explored the integration of nanoparticles loaded with therapeutic drugs within the 3D-printed blood vessels. Specifically, rapamycin, a potent drug for preventing restenosis, was encapsulated within the nanoparticles to enable controlled drug release. This approach aimed to address the challenge of restenosis by delivering the drug directly to the affected site and maintaining its therapeutic concentration over an extended period. Additionally, the study investigated the incorporation of endothelial progenitor cells (EPCs), which promote re-endothelialization essential for vascular regeneration and long-term vessel functionality, within the artificial blood vessels. The 3D-printed blood vessels provide an ideal environment for the integration and growth of these cells, further enhancing their regenerative potential. By combining 3D printing technology, drug-loaded nanoparticles, and EPCs, this study demonstrated the potential of this approach in fabricating functional artificial blood vessels.

12 January 2024 in International Journal of Bioprinting
Verified
Journal Article
Open access
PDF file
JZJie Zhang
Jie Zhang
JCJaewoo Choi
Jaewoo Choi
HLHye Ji Lim
Hye Ji Lim
DYDeokhyeon Yoon
Deokhyeon Yoon
DLDong Myoung Lee
Dong Myoung Lee
SKSang Mo Kwon
Sang Mo Kwon
Vascular regeneration plays a critical role in the treatment of cardiovascular diseases and in tissue engineering applications. In this study, we fabricated and characterized statin/curcumin-loaded nanoparticles for potential applications in vascular regeneration. The nanoparticles exhibited consistent spherical shape and sizes, indicating reproducibility and stability of the fabrication process. The sustained release of the loaded drugs from the nanoparticles indicated their suitability for controlled and prolonged drug delivery. Biocompatibility assessments revealed that the nanoparticles were nontoxic even at high concentrations and over extended periods. Moreover, the incorporation of statin within the nanoparticles enhanced the proliferative capacity and functional abilities of endothelial progenitor cells, thereby promoting angiogenesis and vascular repair. Co-administration of curcumin with statin further augmented the therapeutic effects by reducing intracellular reactive oxygen species levels and providing antioxidant protection against oxidative stress. Furthermore, we successfully integrated these nanoparticles into artificial blood vessels (ABVs) using three-dimensional printing technology, creating customizable constructs capable of supporting vascular regeneration. The viability and proliferative capacity of cells within the ABVs were preserved, which has potential for targeted drug delivery and localized therapy. In in vivo models of hindlimb ischemia, transplantation of nanoparticle-loaded ABVs resulted in significant improvements in terms of recovery speed and blood flow. Histological analysis confirmed the enhanced expression of vascular-related markers, indicating improved angiogenesis. Collectively, our findings demonstrate the potential of statin/curcumin-loaded nanoparticles as a promising approach for vascular tissue engineering and regenerative medicine. These nanoparticles offer controlled drug delivery, biocompatibility, and enhanced regenerative properties, suggesting that they are valuable tools for promoting vascular regeneration and advancing therapeutic interventions for cardiovascular diseases. Further research is required to fully elucidate the mechanisms of action and optimize their clinical applications.

31 July 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Kyeong Hyeon LEEKyeong Hyeon LEE
Kyeong Hyeon LEE
KKKangmin Kim
Kangmin Kim
JHJu Hyuk Han
Ju Hyuk Han
Kyung Taek OhKyung Taek Oh
Kyung Taek Oh
DKDae Kyong KIM
Dae Kyong KIM
Background/Objectives: The pericellular matrix (PCM), a highly hydrated hyaluronan (HA)-rich extracellular structure surrounding keratinocytes, serves as a critical regulator of cellular protection, mechanobiological signaling, and epidermal microenvironmental homeostasis. Increasing evidence suggests that age- and stress-associated degradation of the HA-rich PCM contributes to impaired regenerative capacity and increased cellular vulnerability. Recombinant human hyaluronan and proteoglycan link protein 1 (rhHAPLN1) has emerged as a promising PCM-stabilizing biomolecule; however, its therapeutic application remains limited by poor skin permeability resulting from the barrier properties of the stratum corneum and the molecular size constraints governing hydrophilic macromolecule delivery. Methods: In the present study, we developed Soluball®, a dodecylamine-templated mesoporous silica-based carrier system designed to enhance the transdermal delivery of rhHAPLN1. Results: In vitro analyses demonstrated that rhHAPLN1 effectively preserved both the structural integrity and functional hydrodynamic volume of the PCM against hyaluronidase (HAdase)-induced degradation in HaCaT keratinocytes. Furthermore, rhHAPLN1 exhibited no significant cytotoxicity at concentrations up to 1 μg/mL and significantly enhanced keratinocyte proliferation under serum-free conditions. Physicochemical characterization revealed that Soluball® possessed a relatively uniform particle size distribution (284.6 nm), a high specific surface area (1048 m2/g), and a mesoporous architecture with an average pore diameter of 3.8 nm, supporting efficient loading of hydrophilic biomolecules. Ex vivo permeation studies using human cadaver skin demonstrated that Soluball®-encapsulated rhHAPLN1 (H-S powder) significantly enhanced cumulative transdermal permeation compared with free rhHAPLN1 (5.54% vs. 0.88%, respectively). To further evaluate platform versatility, water-soluble Vitamin C was employed as a secondary model cargo. Vita-Soluball® exhibited markedly enhanced permeation across both Strat-M® artificial membranes and pig epidermis, achieving cumulative permeation values of 119.12 ± 9.38 μg/mL and 150.39 ± 29.20 μg/mL, respectively. Conclusions: Collectively, these findings suggest that rhHAPLN1 functions as an effective stabilizer of the HA-rich PCM and that Soluball® enhances the transdermal delivery of hydrophilic biomolecules. Overall, Soluball® may represent a promising transdermal delivery platform for hydrophilic biomolecules, although further in vivo validation is warranted.